An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the ILDR2 Function-blocking Antibody BAY1905254 in Patients With Advanced Solid Tumors

What is the purpose of this trial?

The main purpose of this clinical study is to determine the most appropriate dose of the study medication that can be safely given to subjects, and to look at how the study medication is changed and distributed by the body.



Bayer Healthcare Pharmaceuticals, Inc.

Start Date: 01/15/2019

End Date: 05/01/2021

Last Updated: 01/16/2019

Study HIC#: 2000023462

Get Involved

For more information about this study, contact:
Stephanie Rosini
+1 203-785-2963
stephanie.vetter@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image